Adlai Nortye Group Ltd. has announced that it will present an update on its AN4035 program during the upcoming 38th EORTC-NCI-AACR Symposium. This event is scheduled to take place from November 18 to 20, 2026, in Barcelona, Spain. The presentation will highlight the latest findings regarding AN4035, a novel cancer therapy designed to enhance treatment efficacy.

As a clinical-stage biotechnology company, Adlai Nortye focuses on developing innovative cancer therapies. The company aims to address significant unmet medical needs in oncology, particularly through its unique drug candidates. With a strong emphasis on research and development, Adlai Nortye is positioned to make meaningful contributions to cancer treatment.

The recent filing reveals that an abstract for AN4035 has been selected for an oral presentation, which is a significant recognition of the program's potential. Dr. Archie Tse, President and Head of Research & Development at Adlai Nortye, expressed enthusiasm about this opportunity, stating, "We are delighted that an AN4035 abstract has been selected for an oral presentation at ENA for the second time." This underscores the importance of the findings that will be shared with the oncology community.

The oral presentation will cover translational and combination data supporting the ongoing Phase I study of AN4035, including its evaluation alongside EGFR blockade. AN4035 is a first-in-class antibody-drug conjugate (ADC) targeting CEACAM5, armed with a proprietary pan-RAS(ON) inhibitor payload. This innovative approach is designed to broaden the therapeutic window, making it a promising candidate for combination therapies.

The details of the oral presentation are as follows: it will be titled "Tumor-selective delivery of a pan-RAS(ON) inhibitor by the novel CEACAM5-targeted ADC AN4035 expands the therapeutic window and enables potent, well-tolerated combination with EGFR blockade." Dr. Tse will be the speaker, and the session is part of the plenary discussions on targeting the RAS pathway.

Adlai Nortye's focus on developing precision therapies positions it well within the pharmaceutical preparations industry, especially as competition intensifies among companies seeking to innovate in cancer treatment. The results of the AN4035 program could have far-reaching implications for patients and healthcare providers alike.

As the company prepares for the symposium, stakeholders will be keenly watching how the presentation is received and what further developments may arise from the ongoing clinical trials. The filing does not specify what happens next, but the anticipation surrounding the symposium indicates a pivotal moment for Adlai Nortye and its innovative approaches to cancer therapy.